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Abstract 141 
Background: Rare DNA breakage-repair disorders predispose to infection and 142 
lympho-reticular malignancies. Hematopoietic cell transplantation (HCT) is curative 143 
but co-administered chemo- or radio-therapy is damaging due to systemic radio-144 
sensitivity. We collected HCT outcome data for Nijmegen Breakage syndrome 145 
(NBS), DNA ligase IV deficiency (LIG4), Cernunnos-XLF deficiency and ataxia-146 
telangiectasia. 147 
Methods: Data from 38 centres worldwide, including indication, donor, conditioning 148 
regimen, graft-versus-host disease (GvHD) and outcome were analyzed. 149 
Conditioning was classified as myeloablative (MAC) if it contained radiotherapy or 150 
alkylators and reduced intensity (RIC) if no alkylators and/or fludarabine ≤150 mg/m2 151 
and cyclophosphamide ≤ 40 mg/kg were used. 152 
Results: 55 new, 14 updated and 18 previously published patients were analyzed. 153 
Median age at HCT was 48 (range 1.5 – 552) months. 29 were transplanted for 154 
infection, 21 malignancy, 13 bone marrow failure, 13 pre-emptively, 5 had multiple 155 
indications, and 6 had no information. 22 received MAC, 59 RIC, 4 were infused;- 156 
information unavailable for 2. 73/77 patients with LIG4, Cernunnos-XLF deficiency or 157 
NBS received conditioning. Survival was 53/77 (69%), worse for MAC than RIC 158 
(p=0.006). Most deaths occurred early post-transplant suggesting poor tolerance of 159 
conditioning. Survival in ataxia-telangiectasia patients was 25%. 41/83 patients 160 
experienced aGvHD (49%): less in RIC compared to MAC, 26/56 (46%) vs 12/21 161 
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(57%) (p=0.45). Median follow-up was 35 (range 2-168) months. No secondary 162 
malignancies were reported during 15 years follow-up. Growth and developmental 163 
delay remained post-HCT; immune-mediated complications resolved. 164 
Conclusion: RIC-HCT resolves DNA repair disorder-associated immunodeficiency. 165 
Long-term follow-up is required for secondary malignancy surveillance. Routine HCT 166 
for ataxia-telangiectasia is not recommended. 167 
Key words: Ataxia-Telangiectasia, Cernunnos-XLF deficiency, DNA repair 168 
disorders, DNA Ligase 4 deficiency, Hematopoietic stem cell transplantation, 169 
Nijmegen Breakage syndrome,  170 
 171 
Abbreviations: 172 
AT - Ataxia-Telangiectasia  173 
ATG – anti-thymocyte globulin 174 
ATM - Ataxia-Telangiectasia mutated 175 
Cernunnos-XLF – Cernunnos –XRCC4 like factor 176 
CIBMTR  - Center for International Blood and Marrow Transplant Research  177 
CMC - cytomegalovirus 178 
DNA-dsb – DNA double strand breaks 179 
DNA-PKcs – DNA protein kinase catalytic subunit 180 
EBMT - European Society for Blood and Marrow Transplantation 181 
EBV - Epstein-Barr virus 182 
GvHD - graft-versus-host disease 183 
Gy - Gray 184 
HCT - Hematopoietic cell transplantation 185 
IEWP - Inborn Errors Working Party 186 
LIG4 - DNA ligase 4 deficiency 187 
MAC - Myeloablative conditioning 188 
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NBS – Nijmegen Breakage Syndrome 189 
NHEJ - non-homologous end joining 190 
NHEJ1 - Non-Homologous End Joining Factor 1 191 
PIDTC - North American Primary Immunodeficiency Treatment Consortium 192 
PTLD - post-transplant lymphoproliferative disorder 193 
RAG1/2 - recombination activating gene 1/2 194 
RIC - reduced intensity conditioning 195 
SCETIDE - Stem CEll Transplant for primary Immune Deficiencies in Europe 196 
SCID - severe combined immunodeficiency 197 
XRCC4 - X-ray repair cross-complementing protein 4 198 
 199 
 200 
Clinical implications 201 
Hematopoietic cell transplant cures DNA breakage-repair disorders. Cernunnos-XLF 202 
deficiency, LIG4 and Nijmegen breakage syndrome patients receiving alkylator or 203 
radiotherapy pre-conditioning have worse survival than those receiving reduced 204 
intensity conditioning.   205 
Capsule summary206 
Hematopoietic cell transplant cures DNA breakage-repair disorders. Cernunnos-XLF 207 
deficiency, LIG4 and Nijmegen breakage syndrome patients receiving alkylator or 208 
radiotherapy pre-conditioning have worse survival than those receiving reduced 209 
intensity conditioning.  AT patients have very poor outcome. 210 
211 
212 
 213 
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Introduction 214 
Maintenance of genomic stability requires repair of DNA, damaged through 215 
endogenous processes such as meiotic and mitotic replication errors, and 216 
exogenous processes including exposure to oxidising radicals, DNA-damaging 217 
chemicals, ultra-violet and ionizing radiation. Several repair pathways regulate the 218 
cell cycle, and recognize and repair DNA damage. One of the most serious events to 219 
threaten genomic stability, DNA-double strand breaks (DNA-dsb), if unchecked, lead 220 
to loss of genomic material, mutagenesis and oncogenesis or cell death1. Two 221 
pathways are employed to repair such damage: homologous recombination, which 222 
functions primarily in dividing cells and S phase, and requires a homologous 223 
template to maintain replication accuracy, and non-template dependent non-224 
homologous end joining (NHEJ), which is particularly employed during phases of the 225 
cell cycle when a homologous template is not present. The latter is an especially 226 
error-prone process with some loss of DNA information at the site of the DNA-dsb2.   227 
 228 
Development of normal adaptive immunity requires generation of a wide range of T- 229 
and B-lymphocyte receptors to recognise unique antigen/MHC combinations and 230 
provide effective defence against a broad repertoire of pathogens. Many genetically 231 
diverse receptors are generated in the thymus and bone marrow, by breaking, 232 
stochastically rearranging and re-joining DNA sequences coding for antigen 233 
receptors, a process known as VDJ recombination. Additional diversity is created in 234 
B-lymphocytes during immunoglobulin class switch recombination, and somatic 235 
hypermutation. The DNA repair mechanisms required to maintain somatic genomic 236 
stability are also utilized during lymphocyte VDJ recombination to repair intermediate 237 
DNA hairpins and physiological DNA-dsb created following activation of 238 
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recombination activating gene 1 and 2 (RAG1/2)3. Seven ubiquitously-expressed 239 
proteins are associated with NHEJ – Ku70/80 and DNA-PKcs, which stabilize the 240 
DNA break, the DNA endo/exonuclease Artemis, important for processing RAG-241 
induced hairpin intermediate joins and the DNA ligase 4, Cernunnos-XLF and 242 
XRCC4 complex, which together are responsible for the ligation step. Additionally, 243 
ataxia-telangiectasia-mutated and nibrin proteins are involved in the initial cell cycle 244 
arrest and recruitment of NHEJ proteins to the breakage site4 (Supplementary Figure 245 
1).  246 
Defects in the lymphoid-specific RAG1/2 proteins lead to T-lymphocyte negative, B-247 
lymphocyte negative, natural killer lymphocyte positive (T-B-NK+) severe combined 248 
immunodeficiency (SCID) (5). Defects in Artemis, DNA-PKcs, DNA Ligase 4 and 249 
Cernunnos-XLF proteins also lead to T-B-NK+ SCID, and combined 250 
immunodeficiencies, often associated with other developmental anomalies, 251 
particularly microcephaly in patients with DNA Ligase 4 and Cernunnos-XLF 252 
deficiency, as a result of the ubiquitous expression of these proteins6-14. 253 
Hematopoietic cell transplantation (HCT) is curative for T-B-NK+ SCID, but best 254 
results with donor myeloid chimerism and long-term immune reconstitution are 255 
obtained if preparative chemotherapy is administered prior to transplantation15. 256 
However, in Artemis-deficient radiosensitive SCID patients, although overall survival 257 
is equivalent to patients with RAG-deficient SCID, significant long-term sequelae 258 
result from the administration of alkylating agents, which are required to gain donor 259 
stem cell engraftment with sustained, long-term thymopoiesis. The use of alkylating 260 
chemotherapy does not result in increased short-term toxicities or increased 261 
transplant-related mortality, but long-term effects on growth and development are 262 
observed, due to the effect of chemotherapy on other somatic cells that harbor the 263 
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genetic defect15. Similar significant effects of chemotherapy are seen in patients with 264 
Fanconi anaemia (OMIM 227650) and dyskeratosis congenita (OMIM 127550) – 265 
both DNA fragility syndromes16,17. Given the systemic nature of the DNA-dsb defect 266 
in other DNA-dsb repair disorders and the finding that the radiosensitivity is generally 267 
more severe than in Artemis-deficiency, it is possible that pre-administration of DNA-268 
damaging chemotherapy prior to transplantation will lead to significant systemic 269 
morbidity and possible increased mortality.  270 
Due to the primary immunodeficiency phenotype and the frequent occurrence of 271 
malignancy, a number of patients with DNA-dsb repair disorders have undergone 272 
HCT10-13,18-28. To assess outcome of HCT for DNA-dsb repair disorders, we surveyed 273 
patients transplanted for DNA ligase 4 deficiency (LIG4), Cernunnos-XLF deficiency 274 
(XLF or NHEJ1), Nijmegen Breakage Syndrome (NBS) and Ataxia-Telangiectasia 275 
(AT), using base line data from Stem CEll Transplant for primary Immune 276 
Deficiencies in Europe (SCETIDE), Inborn Errors Working Party (IEWP) of the 277 
European Society for Blood and Marrow Transplantation (EBMT) registry, the Center 278 
for International Blood and Marrow Transplant Research (CIBMTR) and the North 279 
American Primary Immune Deficiency Treatment Consortium (PIDTC) and 280 
supplemented with additional information from individual centers where available. 281 
Patients with mutations in RAG1/2 and DCLRE1C (encoding Artemis) were excluded 282 
from the study, as HCT outcomes for these conditions have recently been reported15. 283 
  284 
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Methods 285 
Data collection 286 
Data on patients with defined mutations in LIG4 (OMIM 606593), NBN (OMIM 287 
602667), NHEJ1 (OMIM 611290) and ATM (OMIM 607585), who had undergone 288 
HCT were gathered from the IEWP of EBMT, SCETIDE, CIBMTR and the North 289 
American PIDTC. Further patients were identified from previously published data and 290 
case reports. Centers with identified patients completed a proforma to gather data on 291 
genetic diagnosis, patient demographic, reason for HCT, type and source of HCT, 292 
conditioning regimen employed, rates and severity of graft-versus-host disease 293 
(GvHD) and survival post-HCT. 294 
Inclusion criteria were any patient having a confirmed genetic diagnosis and having 295 
undergone HCT. 296 
The reason to offer HCT was defined as any category or combination of:  297 
• infection, (defined as any listed severe infection or recurrent infections) 298 
• malignancy  299 
• bone marrow failure, (defined as leukopenia, anemia or thrombocytopenia 300 
without the presence of infection or malignancy) 301 
• autoimmunity  302 
• pre-emptive. 303 
Conditioning was categorized as either myeloablative conditioning or reduced 304 
intensity conditioning. Myeloablative conditioning (MAC) was defined as any regimen 305 
using high dose alkylating agents, typically melphalan or busulphan, thiotepa, or total 306 
body irradiation at any dose. Although a low dose 200-400cGy regimen can normally 307 
be considered non-myeloablative, we reasoned that radiation-sensitive cells were 308 
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best not exposed to ionising radiation.  If the regimen did not use alkylating agents 309 
and/or had doses of fludarabine ≤150 mg/m2 and cyclophosphamide ≤ 40 mg/kg it 310 
was defined as reduced intensity conditioning (RIC)29. A modified Fanconi-regimen 311 
was based on fludarabine 120-150 mg/m2 (30 mg/m2/day in 4-5 divided doses), 312 
cyclophosphamide 20-40 mg/kg (in 4 divided doses) with or without anti-thymocyte 313 
globulin (ATG) or alemtuzumab serotherapy30,31 or fludarabine 180/m2 (in 6 divided 314 
doses), busulphan 1.6mg/kg (in 2 divided doses) and cyclophosphamide 40mg/kg (in 315 
2 divided doses)32.  The use of targeted agents such as antibodies, for example 316 
alemtuzumab, did not affect the classification of the conditioning. 317 
The primary outcome that was measured was survival.  Secondary outcome  318 
measures sought were presence, severity and outcome of GvHD, other transplant-319 
related complications and survival. 320 
Analysis 321 
Significance of results was determined by use of Fisher’s exact test, utilising 2x2 322 
contingency tables. A two-tailed p value of ≤ 0·05 was considered significant. 323 
Kaplan-Meier curves were created based on last known status at time of proforma 324 
received, cases where survival was not listed have been excluded from the survival 325 
analysis. All statistics were calculated using GraphPad Prism 6 (GraphPad Software, 326 
Inc., La Jolla, California). 327 
  328 
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Results 329 
Data were collected from 38 centers worldwide, culminating in 55 newly identified 330 
patients, and 14 previously published patients with updated new information, giving 331 
new information on 69 patients. Available data from 18 previously published cases10-332 
14,18-28
 were included where possible, totalling 87 cases. The median age of patients 333 
at HCT was 48 months (range 1.5 - 552 months), 47 were male (54%). 334 
Mutations in LIG4 were most commonly represented, (36 patients, 32 unpublished or 335 
with new information) (Table S1), 26 with NBN mutations (17 unpublished or with 336 
new information) (Table S2), 17 with NHEJ1 mutations (12 unpublished or with new 337 
information) (Table S3), and 8 with ATM mutations (all with new information, 2 338 
previously published, updated in this report) (Table S4). All patients received 339 
allogeneic hematopoietic stem cells, except two published cases who died 340 
immediately prior to HCT, whilst receiving MAC, but whose data were included in the 341 
study. 342 
Information was provided on the primary reason for HCT in 83 patients (figure 1). 343 
Significant or repeated infections were the most commonly cited reason (29 patients, 344 
35% - 12 with LIG4 mutations, 11 with NHEJ1 mutations), 13 patients were 345 
transplanted for bone marrow failure (15%) and 21 patients (24%) for malignancy (17 346 
with NBN mutations). Thirteen patients were transplanted pre-emptively on the basis 347 
of a SCID-like diagnosis (15%), 10 with LIG4 mutations. Five patients had a mixture 348 
of the above indications, and in 6 patients, the reason for HCT was not available. 349 
Twenty two patients received MAC, and 59 RIC, of which 30 were based on a 350 
modified Fanconi anaemia conditioning regimen. Four patients received a stem cell 351 
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infusion without prior conditioning, data were unavailable for 2 patients. Two 352 
received radiotherapy (5Gy, 2Gy) as part of the conditioning regimen.  353 
Survival 354 
Of patients with DNA ligase 4, Cernunnos-XLF deficiency and NBS, there were 355 
survival data for 77, of whom 73 received conditioning. Overall survival was 53/77 356 
(69%) (Figure 2A), of whom 2 died from relapse of malignancy giving a transplant-357 
related survival of 71%. One patient with NBS rejected the graft, and is alive with 358 
disease. One rejected and succumbed to malignancy. Survival among those 359 
receiving myeloablative conditioning was significantly worse at 41% (7/17) compared 360 
with 79% (44/56) for those receiving reduced intensity conditioning, (p=0·006) 361 
(Figure 2B), describing 2 patients who died of malignancy relapse as survivors. 362 
There was no significant difference in transplanted-related mortality between those 363 
who received a modified Fanconi or other reduced intensity conditioning regimens 364 
(p=0·13). The Kaplan Meier curve demonstrates that the majority of deaths occur 365 
early in the course of transplant, particularly in those receiving myeloablative 366 
conditioning, suggesting poor tolerance of the conditioning regimen.  367 
In patients with Ataxia-Telangiectasia, overall survival was 25%. Of the 2 patients 368 
who survived, both received a modified Fanconi conditioning regimen and neither 369 
experienced GvHD, unlike all patients who received myeloablative conditioning. The 370 
6 patients who died experienced GvHD grade 2-3 (67%%), despite well-matched 371 
donors. Death was due to multi-organ failure, viral activation or post-transplant 372 
lymphoproliferative disorder (PTLD). 373 
Transplant-related survival in the entire cohort for whom data were available was 374 
66% (56/85), with a survival of 75% (45/60) following reduced intensity conditioning 375 
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and 32% (7/22) following myeloablative conditioning (p= 0·0006). There was no 376 
significant difference in outcome between those who underwent HCT for malignancy 377 
(12/22 survivors) or for other indications (37/57 survivors, p=0·44). There was no 378 
significant difference in survivors for those receiving RIC (11/17) or MAC (1/5) 379 
conditioning when malignancy was the reason for HSCT (p=0·14). There was also 380 
no significant difference in survivors for those receiving RIC (5/25) or MAC (4/9) 381 
conditioning when infection was the reason for HSCT (p=0·09). There were too few 382 
cases who were transplanted for bone marrow failure to make a similar comparison. 383 
There were no differences in survival between donor sources whether matched 384 
sibling, matched unrelated or mis-matched unrelated donors were used (18/25, 385 
20/27, 5/8 respectively). 386 
Graft versus host disease 387 
Data on presence or absence of acute (a) GvHD was available for 83 patients; in 41 388 
of these, aGvHD was present (49%). Of the reported patients with aGvHD, 24 (59%) 389 
had mild (grade 1- 2), and 15 (37%) had severe (grade 3-4) aGvHD (a grade was 390 
unavailable for 2 patients). Rates of aGvHD were lower in the RIC group, 26/56 391 
cases (46%) for which data were available, compared to the MAC group, in whom 392 
12/21 cases (57%) experienced aGvHD although this was not statistically significant 393 
(p=0·45). Three of 4 patients who received infused stem cells with no pre-394 
conditioning experienced aGvHD grade 1, 3 and 4 respectively. There was no 395 
significant difference in survival between those experiencing grades 0-1 compared 396 
with grades 2-4 aGvHD (p=0·22). 397 
Mortality 398 
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Overall mortality was 29/85 (34%) - information was unavailable for 2 previously 399 
published patients24. Two patients died of multi-organ failure during the conditioning 400 
process – both received full myeloablative conditioning. Eleven others died of multi-401 
organ failure post-transplantation, making multi-organ failure the most common 402 
cause of death (45%). Eleven deaths were predominantly infectious (38%) 403 
 404 
Other Complications 405 
The most common non-aGvHD complication was viremia due to adenovirus, 406 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) or a combination, reported in 407 
24/79 patients (30%), of whom 6 died. There were 6 cases (8%) of EBV-related 408 
PTLD. Six patients (8%) experienced severe mucositis, 14 developed chronic (c) 409 
GvHD (18%). Seven patients rejected the graft – 2 after stem cell infusion (1 with 410 
serotherapy), 2 after T-lymphocyte depleted transplants (1 myeloablative, 1 reduced 411 
intensity conditioning) and 3 after MAC or RIC transplants. Patients receiving RIC 412 
were less likely to develop severe mucositis, veno-occlusive disease or PTLD than 413 
those who received MAC (7/59 vs 8/22, p=0.0215). 414 
 415 
Follow up 416 
Given the retrospective and multi-institutional nature of the study, detailed 417 
information regarding long term (> 5years) follow up was scarce. Median length of 418 
follow up was 35 months (range 2-168 months). No secondary malignancies were 419 
reported during the follow up period, which although short overall, does include 420 
patients with almost 15 years follow up. Pre-existing growth retardation and 421 
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developmental issues appear to remain post- HCT: more detailed examination would 422 
be required to determine whether HCT ameliorates these features. A predisposition 423 
to infection or hematological cytopenia pre-existing before HCT appears to have 424 
been abolished. 425 
 426 
  427 
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Discussion 428 
Many patients with DNA-dsb repair defects exhibit immunodeficiency, ranging from 429 
mild to severe combined immunodeficiency. They are at increased risk of developing 430 
lymphoid malignancy. Allogeneic HCT is curative for many immunodeficiencies33. 431 
Establishment of effective DNA repair mechanisms in lymphoid progenitors leading 432 
to restoration of functional adaptive immunity may prevent the future development of 433 
lymphoid malignancy in this cohort of patients. Lymphoid malignancy is difficult to 434 
treat effectively when established because of the aggressive nature of the tumours 435 
and poor tolerance of patients to cytotoxic radio- and chemotherapy34. It is therefore 436 
a reasonable strategy to consider HCT in these patients. However, as most patients 437 
have some residual immunity, and even in the SCID phenotype, natural killer cells 438 
are present, rejection and poor stem cell engraftment are likely without some 439 
preparative cytoreductive pre-conditioning. The systemic nature of the genetic 440 
defect, however, increases the risk of substantial morbidity or mortality from 441 
chemotherapy or ionising radiation administered prior to transplantation. Only a few 442 
small case series of patients with DNA-dsb repair defects undergoing HCT have 443 
been published. To date there has been no formal large case series from which to 444 
gauge experience.  445 
We now report a multi-institutional retrospective survey on outcome of HCT for 55 446 
previously unpublished patients and update information for 18 previously reported 447 
patients with DNA-dsb repair defects. We have demonstrated that HCT can correct 448 
the hematopoietic defect and underlying immunodeficiency. Furthermore we have 449 
demonstrated that survival is significantly superior when reduced intensity 450 
conditioning is used. It is likely that chemotherapy agents, especially alkylating 451 
agents, induce systemic double strand breaks, which are not readily repaired 452 
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because of the underlying genetic defect. These systemic double strand breaks may 453 
contribute to the early mortality seen following myeloablative therapy. This 454 
intolerance, clinically manifest as severe toxicity, sometimes followed by higher 455 
grade GvHD, suggests that when considering HCT, a reduced intensity conditioning 456 
regimen should be used in patients with known ionising radiation sensitivity and/or 457 
proven diagnosis of a DNA-dsb repair defect, and that radiotherapy should be 458 
omitted. Given the equivalence of outcome results when comparing modified 459 
Fanconi anemia-based regimens with other reduced intensity regimens, the former 460 
may be preferred. Longer term-follow up is required to determine impact of HCT on 461 
future prevention of lymphoid malignancy. 462 
The rate of aGvHD overall was 49%, of which 37% was grades 3-4. The rate of 463 
cGvHD was 18%. The incidence of severe (grade 3-4) aGvHD and cGvHD is higher 464 
than that reported for transplantation of patients with other primary 465 
immunodeficiencies35-38. It is not clear whether this is due to the greater use of 466 
matched unrelated donors, rather than matched sibling donors (although, in the 467 
modern era, outcome of HCT using matched siblings or unrelated donors 468 
approaches equivalence), particularly in those receiving reduced intensity 469 
conditioning. Significant co-morbidities may also have contributed to the increased 470 
incidence of GvHD. However, it may be that the underlying molecular defect causing 471 
impaired DNA repair and reduced cellular repair capability predisposes to GvHD 472 
following cellular damage, as is found in Fanconi anemia or dyskeratosis 473 
congenita17,39. 474 
Patients showed a range of other early post-HCT complications in addition to GvHD. 475 
Most common were viral reactivations, which in the case of EBV led to PTLD in 6 476 
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patients. Severe mucositis and veno-occlusive disease were commonly 477 
encountered.   478 
Three patients experienced veno-occlusive disease and two who had undergone 479 
transplant for malignancy, experienced relapse of the primary malignancy. Three 480 
patients developed autoimmune thyroid disease, and autoimmune cytopenias were 481 
also manifest.  482 
Within this patient cohort there are few data on long-term follow up. Transplantation, 483 
unsurprisingly given the systemic nature of the defect, appears not to improve the 484 
effects of the primary disease on growth or neurological development. It may be, as 485 
in patients with Artemis-SCID, that use of any alkylating agent leads to long-term 486 
sequalae15. It will be difficult to predict whether growth or development has been 487 
improved or deteriorated as a result of chemotherapy, given the scarce data 488 
available on the natural history of these diseases, and the variability of phenotype 489 
already reported. However, determining the long-term and late beneficial and 490 
adverse effects of HCT in DNA-dsb defects will be important to inform about the 491 
utility of this treatment approach. A recent report on a cohort of patients with 492 
mutations in NBN documented poor survival in those developing malignancy24. 493 
Given the good survival outcome in this cohort amongst those who received reduced 494 
intensity conditioning regimens – a pre-emptive approach to transplant may be 495 
considered. Of particular importance, therefore, will be long-term follow up to 496 
determine frequency of secondary malignancies – not reported so far in other 497 
primary immunodeficiency transplant series, but a well-recognised complication in 498 
patients transplanted for Fanconi anemia39.  499 
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Whilst the outcome of HCT in patients with mutations in LIG4, NBN and NHEJ1 is 500 
favourable, particularly when reduced intensity conditioning regimens are employed, 501 
the data for patients with Ataxia-Telangiectasia undergoing HCT are disappointing. 502 
Whether this is specifically due to the use of myeloablative conditioning regimens, or 503 
the presence of malignancy, precipitating transplantation as a therapeutic option, is 504 
not clear. With current results, it is difficult to recommend HCT as a treatment option 505 
for patients with Ataxia-Telangiectasia, except in clinical trials. In contrast, patients 506 
with the other conditions described have transplant outcomes similar to other primary 507 
immunodeficiencies when choosing a reduced intensity conditioning. Therefore, 508 
transplantation could be considered more favourably as a pre-emptive therapeutic 509 
approach, particularly if radiotherapy is omitted from the conditioning regimen, and 510 
low intensity conditioning regimens are employed. The high rate of post-transplant 511 
complications, including GvHD, remains a concern however, and should drive the 512 
development of alternative low or non-toxic conditioning approaches that relieve 513 
these patients of the deleterious effects of alkylating therapy but enable full T- and B-514 
lymphocyte reconstitution. In the meantime, careful follow up is required to observe 515 
further systemic benefits from transplantation, if any, and importantly to monitor for 516 
long-term adverse events. In the future, gene therapy may be an acceptable 517 
alternative treatment strategy for this group of patients.  518 
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Figure 1. Indication for hematopoietic cell transplantation 722 
Figure 2. Probabilities of overall survival. 723 
A. Kaplan Meier curve showing overall survival of 74 patients with with DNA 724 
ligase 4, Cernunnos-XLF deficiency and Nijmegen Breakage Syndrome 725 
 726 
B. Kaplan Meier curve demonstrating differences in survival of 74 patients with 727 
DNA ligase 4, Cernunnos-XLF deficiency and Nijmegen Breakage Syndrome 728 
transplanted using a reduced intensity or myeloablative conditioning 729 
regimens. 730 
 731 
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Supplementary Tables and Figures legend. 
 
 
Table S1. Characteristics of patients with DNA ligase 4. 
Table S2. Characteristics of patients with defects in NBN. 
Table S3. Characteristics of patients with defects in NHEJ1. 
Table S4. Characteristics of patients with Ataxia Telangiectasia. 
 
Figure S1. V(D)J Recombination 
Figure 1A. 
A. DNA is uncoiled at transcription “factories” within the cell, where the 
associated recombination and repair proteins co-localize. 
B. The lymphoid specific recombinase activating gene 1 and 2 (RAG1/2) 
proteins recognize and bind the recombination signal sequences (RSS) 
that flank the V(D)J gene segments, and introduce site-specific DNA-
DSBs.  
C. The phosphorylated blunt signal ends and the covalently sealed hairpin 
intermediate of the coding end are held together by the RAG complex. 
Figure 1B.  
D. The MRN complex binds the broken DNA ends and activates ATM which 
initiates cell cycle arrest and attraction of the repair proteins. H2AX, 53BP1 
and RNF168, and with other proteins stabilize the damaged chromatin. 
Ei. Ku70/Ku80 heterodimer binds the coding ends and recruits DNA-PKcs and 
Artemis, which is required to open the hairpin intermediates. The covalently 
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sealed hairpin intermediate is randomly nicked by the DNA-Pkcs/Artemis 
complex, which generates a single stranded break with 3’ or 5’ overhangs.  
Eii. XRCC4, DNA ligase 4 and cernunnos-XLF (C-XLF) co-associate and are 
recruited to the ends. The signal ends are directly ligated by the XRCC4/DNA-
LIG4/C-XLF complex. The opened hairpin intermediate is modified by 
polymerases, exonucleases and the lymphoid-specific terminal 
deoxynucleotidyl transferase (TdT), before  
Eiii. being repaired and ligated by the XRCC4/DNA-LIG4/C-XLF complex 
(Reproduced from reference 43 with permission) 
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Table S1. Characteristics of patients with DNA ligase 4. 
 
Patient Age in 
months 
at HSCT 
Sex 
Indication Donor/ 
Stem cell 
source 
conditioning aGvHD Complications Follow up 
(months) 
Outcome 
New cases 
        
1 
Transplant 1 
 
Transplant 2 
5 
M 
 
9 
Infection 
 
 
Graft failure 
MUD 
CB 
 
MUD 
BM 
Alemtuzumab 
1mg/kg 
 
Flu 150mg/m2* 
Melph 70mg/m2 
Alemtuzumab 
1mg/kg 
nil 
 
 
nil 
Initial graft failure 
chronic lung disease 
 
EBV viraemia and 
colitis, 
hypothyroidism, 
bronchiolitis 
obliterans 
- 
 
 
83 
Alive 
 
 
Alive 
2 8 
F 
Autoimmunity 
Omenn 
phenotype 
MMUD 5/6 
CB 
 Flu 150mg/m2** 
 Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
Grade 2 
Skin, 
liver 
nil 48 Alive 
3 17 
M 
Pre-emptive MUD 
BM 
Flu 150mg/m2* 
Melph 70mg/m2 
Alemtuzumab 
1mg/kg 
Grade 
3, Skin 
and Gut 
cGvHD, 
EBV & Adenovirus 
viraemia colitis, HTN, 
Cholecystitis, 
36 Alive 
4 18 
M 
Infection MUD 
PBSC 
CD34+ 
selected 
Flu 150mg/m2* 
Melph 140mg/m2 
ATG (dose n/a) 
nil Dilated 
cardiomyopathy 
83 Alive 
5 18 
M 
n/a MUD 8/8 
BM 
 Flu 150mg/m2* 
 Melph 70 
mg/m2 
 Alemtuzumab 
1mg/kg 
Grade 3 n/a 24 Alive 
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6 
Transplant 1 
 
Transplant 2 
21 
M 
 
23 
Infection 
 
 
Graft failure 
MMFD 
BM 
 
MMFD 
BM 
Nil 
 
 
Bu 12.9mg/kg * 
Flu 120mg/m2 
 Alemtuzumab 
0.3mg/kg 
nil graft failure 
 
 
mucositis, left 
arycartilage fracture, 
synechia of anterior 
vocal cord 
 
 
 
143 
Alive 
 
 
Alive 
7 20 
F 
InfectionSCID 
phenotype 
 
 
MFD 
BM 
Flu 150mg/m2* * 
Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
nil sepsis 
 
2 alive 
8 28 
M 
BMF MUD 
BM 
Flu 150mg/m2* 
Melph 70mg/m2 
Alemtuzumab 
1mg/kg 
nil nil 46 Alive 
9 28 
F 
n/a MUD 8/8 
BM 
 Flu 150mg/m2* 
 Melph 70 
mg/m2 
 Alemtuzumab 
 1mg/kg 
nil n/a 36 Alive 
10 31 
F 
Infection MMFD 
BM 
 nil Grade 
3, Skin, 
Gut 
Developmental delay 142 Alive 
11 43 
F 
BMF MUD 
BM, buffy 
coat 
enrichment, 
plasma 
reduction 
Flu 150mg/m2 * * 
Cy 40mg/kg 
 Alemtuzumab 
1mg/kg 
nil nil 24 Alive 
12 47 
M 
Infection MFD 
BM 
Flu 150mg/m2 * * 
Cy 20mg/kg 
 ATG 30mg/kg 
nil nil 15 Alive 
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13 52 
F 
Infection MMFD 9/10 
BM 
Flu 150mg/m2* * 
Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
nil CMV viraemia, 
EBV-PTLD 
50 Alive 
14 54 
M 
Infection 
Autoimmunity 
BMF 
MSD 
BM 
Flu 150mg/m2* * 
Cy 40mg/kg 
ATG 7.5mg/kg 
Grade 1 
skin 
Limited cGvHD 
(resolved) 
Autoimmune 
hypothyroidism 
45 Alive 
15 75 
F 
BMF MUD 9/10 
BM 
Bu 2.4mg/kg * * 
Flu 180mg/m2 
Cy 40mg/kg 
Alemtuzumab 
1.5mg/kg 
nil nil 22 Alive 
16 83 
F 
BMF MUD 
PBSC 
Flu 150mg/m2* * 
Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
nil nil 21 Alive 
17 116 
F 
BMF MMUD 
5/6 
BM 
Flu 150mg/m2 * * 
Cy 40mg/kg 
ATG 10mg/kg 
Grade 1 
skin 
PRES 
cGVHD - skin and 
mucosa 
Mixed chimerism 
12 Alive 
18 120 
M 
Infection MSD 
BM 
Flu 40mg/m2 * * 
Cy 24mg/kg 
ATG 3mg/kg 
nil nil 22 Alive 
19 11 
M 
Infection 
SCID 
phenotype 
MUD 
CB 
 Flu 90mg/m2* 
 Melph 
114mg/m2 
 
nil MOF 2 Dead 
20 22 
F 
Infection MRD 
BM 
Bu 4mg/kg * 
Flu 120mg/m2 
Melph 140mg/m2 
  
nil Heart failure,multi-
organ failure from 
D+1 
5 days Dead 
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21 33 
M 
Infection MUD 
BM 
Flu 150mg/m2* 
Melph 140mg/m2 
ATG (dose n/a) 
Grade 2 
Skin, 
gut 
VOD, mucositis, died 
multi-organ failure, GI 
bleeding 
n/a Dead 
22 49 
F 
Infection 
BMF 
MMUD 
CB 
Flu 150mg/m2 * *  
Cy 40mg/kg 
ATG 10mg/kg 
Grade 3 
gut 
pericardial effusion, 
SVT, MAS 
7 Dead 
23 8 
M 
Pre-emptive MUD 
BM 
Treo 42g/m2*** 
Flu 150mg/m2 
ATG 10mg/kg 
Grade 3 
Skin, 
gut 
Norovirus, TPN 
dependence, graft 
failure, osteopaenic 
fractures, HTN, 
rhinovirus, MOF 
8 Dead 
24 10 
F 
Infection Paternal 
haplo-
identical 
PBSC 
CD34+ 
selected 
Flu 120mg/m2 ***  
Melph 140mg/m2 
TT 10mg/kg 
 
Grade 1 
skin 
GI and pulmonary 
haemorrhage 
1 Dead 
25 13 
M 
Infection 
SCID 
phenotype 
MMUD 9/10 
BM 
Flu 150mg/m2*** 
TT 15mg/kg 
ATG 10mg/kg 
Grade 
3, skin, 
gut, liver 
P. aeruginosa, RSV, 
EBV, CMV, capillary 
leak syndrome 
Pneumopathy 
5 Dead 
26 60 
M 
BMF Maternal 
CD34+ haplo 
 Flu 200 
mg/m2*** 
 Cy 20mg/kg 
 TT 5mg/kg 
ATG 3.gmg/kg 
nil Rejection 
Fungal pneumonia 
6 Dead 
          
Updated 
Cases 
        
2720 
 
M 
49 
Infection MUD 
PBSC 
Flu 150mg/m2 * * 
Cy 40mg/mg 
Alemtuzumab 
Grade 2 
Skin, 
gut 
Autoimmune 
hypothyroidism 
93 Alive 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0.6mg/kg 
YTH24/54 
1.6mg/kg 
2819 F 
6 
Infection 
SCID 
phenotype 
MUD 
BM 
Bu 16mg/kg*** 
Cy 200mg/kg 
Grade 4 
Skin, 
gut 
cGvHD 
resp failure, cardiac 
hypertrophy, renal 
failure, EBV, 
developmental delay, 
raised ICP, tube feed, 
optic neuritis 
103 Alive 
2910 
 
M 
552 
BMF 
MDS 
MSD 
BM 
Bu 12.8mg/kg*** 
Cy 120mg/kg 
nil Severe mucositis, 
CMV 
cGvHD 
? Alive 
3011 F 
19 
Infection 
SCID 
phenotype 
MMUD 
BM (TCD) 
Bu 16mg/kg*** 
Cy 200mg/kg, 
ATG 10mg/kg 
nil EBV-PTLD 2 Dead 
 
3111 F 
2.5 
Pre-emptive 
SCID 
phenotype 
MMUD 
BM 
3/6 
TCD 
Bu 15mg/kg*** 
Cy 200mg/kg 
ATG 10mg/kg 
nil VOD 
Pneumopathy 
1.5 Dead 
3241 
 
M 
212 
BMF TCR/ 
PBSC 
haploidentical 
mother 
Flu 180mg/m2* 
Cy 60mg/kg 
ATG 2.5mg/kg 
 
Grade 3 
GI 
Poor 
immunoreconstitution,  
BK viral infection 
acute renal failure 
12 Dead 
Published 
        
3316 F 
132 
BMF MSD 
BM 
Flu 120mg/m2 * *   
Cy 40mg/kg 
ATG 60mg/kg 
nil Delayed puberty 60 Alive 
3412 
 
F 
4 
SCID 
phenotype 
MUD 
BM 
Flu (dose n/a)*** 
TT (dose n/a) 
nil severe HUS, with 
renal impairment 
8 Alive 
3513 F 
18 
Infection MSD 
cord 
Bu 20mg/kg  *** 
Cy 200mg/kg 
nil Died before HSCT, 
VOD, resp arrest 
- Dead 
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3612 
 
F 
24 
Infection 
Autoimmunity 
Malignancy 
 Myeloablative*** 
No details 
available 
 Died during 
conditioning 
MOF 
aspergillosis 
- Dead 
* Reduced intensity conditioning regimen, ** Fanconi or modified Fanconi regimen, *** Myeloablative conditioning regimen. 
ATG, anti-thymocyte globulin; Bu, busulphan; Cy, cyclophosphamide; Flu, fludarabine; Melph, melphalan; Treo, treosulphan; 
TT, thiotepa; YTH24/54, anti-CD45 monoclonal antibodies 
 
BM, bone marrow; BMF, bone marrow failure; CB, cord blood; CMV, cytomegalovirus; EBV, Epstein-Barr virus; (a)(c)GvHD, 
(acute) (chronic) graft-versus-host disease; GI, gastrointestinal; HSCT, haematopoietic stem cell transplant; HTN, hypertension; 
HUS, haemolytic uraemic syndrome; MAS, macrophage activation syndrome; MFD, matched family donor; MMFD, mismatched 
family donor; MOF, multi-organ failure; MUD, matched unrelated donor; n/a, not available; PBSC, peripheral blood stem cells; 
PRES, posterior reversible encephalopathy syndrome; PTLD, post-transplant lymphoproliferative disease; RSV, respiratory 
syncytial virus; SCID, severe combined immunodeficiency; SVT, supra-ventricular tachycardia; TCD, T cell depleted; TCRa/b, T 
cell receptor alpha/beta depletion; TPN, total parenteral nutrition; VOD, veno-occlusive disease 
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Table S2. Characteristics of patients with defects in NBN. 
 
Patient Age in 
months 
at HSCT 
Sex 
Indication Donor/ 
Stem cell 
source 
conditioning aGvHD Complications Follow up 
(months) 
Outcome 
New cases 
        
37 F 
45 
Autoimmunity MSD 
BM 
Alemtuzumab* * 
1mg/kg 
Flu 150mg/m2 
Cy 20mg/kg 
Grade 2 
Skin 
AIHA 14 Alive 
38 M 
69 
Malignancy TCRa/b 
PBSC 
MUD 9/10. 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 30mg/kg, 
ATG 5mg/kg, 
Rituximab 100mg/m2 
nil Hepatitis 
CMV viraemia 
5 Alive 
39 M 
71 
Infection TCRa/b 
PBSC 9/10 
sibling 
donor 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 20mg/kg, 
ATG 5mg/kg, 
Rituximab 100mg/m2 
nil nil 2 Alive 
40 M 
90 
Malignancy TCRa/b 
PBSC  
MUD 10/10 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 40mg/kg, 
ATG 5mg/kg, 
Rituximab 100mg/m2 
nil hepatitis 6 Alive 
41 F 
107 
Pre-emptive MUD 9/10 
PBSC 
CD34+ with 
T cell add-
back 
1*10^8/kg 
Bu 2mg/kg* * 
Flu 180mg/kg 
Cy 20mg/kg 
Alemtuzumab 
0.5mg/kg 
nil Secondary graft 
loss 
14 Alive with 
disease 
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42 M 
144 
Malignancy MSD 
BM 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 20 mg/kg, 
ATG 5mg/kg 
Grade 1 
skin 
Norovirus, 
adenovirus 
enterocolitis 
16 Alive 
43 F 
205 
EBV-
associated 
LPD 
MSD 
BM 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 30mg/kg, 
ATG, Rituximab 
nil EBV-PTLD 6 Alive 
44 M 
228 
n/a MUD 8/8 
PBSC 
TBI(2Gy),*** 
Flu 150mg/m2 
Grade 2 cGvHD 59 Alive 
45 F 
60 
Malignancy MUD 
PBSC 
TCRa/b 
Bu 4mg/kg,* 
Flu 150mg/m2, 
Cy 40mg/kg, 
ATG 5mg/kg, 
Rituximab 100mg/m2 
Grade 1 
skin 
Mucositis Grade 
2, relapse PTCL 
3 Dead 
46 F 
136 
Malignancy MMFD 
PBSC 
Melph 140mg/m2* 
Flu 120mg/m2, 
Alemtuzumab 
1mg/kg 
nil VOD, MOF, 
sepsis 
2 Dead 
47 F 
204 
BMF MUD 
PBSC 
TCRa/b 
Bu 4mg/kg, * 
Flu 150mg/m2, 
Cy 40mg/kg, 
ATG 5mg/kg, 
Rituximab 100mg/m2 
nil Rejected 10 
months 
Developed T cell 
lymphoma 
16 Dead 
Updated 
cases 
        
4821, 34 
 
F 
27 
Infection MSD 
BM 
Alemtuzumab* * 
1mg/kg 
Flu 150mg/m2 
Cy 20mg/kg 
nil Autoimmune 
hyperthyroidism 
102 Alive 
4921, 34 
 
M 
42 
Pre-emptive MFD 10/10 
BM 
Thoracoabdominal*** 
irradiation 5 Gy 
nil ADV, CMV 
Mucositis 
150 Alive 
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Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
Mixed chimerism 
5034 
 
F 
77 
Malignancy MUD 
BM 
Flu 150mg/m2, * * 
Cy 20mg/kg, 
Alemtuzumab 
1mg/kg 
Grade 1 
Skin 
nil 29 Alive 
5134 
 
M 
110 
Malignancy MFD 
BM 
Flu 150mg/m2, * * Cy 
40mg/kg, 
ATG 70mg/kg, 
Rituximab 750mg/m2 
Grade 3 
Skin 
cGvHD skin, liver 
CMV reactivation 
48 Alive 
5221 
 
M 
240 
Malignancy MUD 
PBSC 
Melph 140mg/m2, * 
Flu 125mg/m2, 
ATG 60mg/kg 
Grade 1 
skin 
nil 99 Alive 
5340 
 
M 
185 
Malignancy MSD 
BM 
Melph 140mg/m2*  
Flu 150mg/m2, 
Alemtuzumab 
1mg/kg 
Grade 1 
Skin /gut 
Toxoplasmosis 1 Dead 
Published 
cases 
        
5422 
 
F 
19 
Infection MUD 
CB 
ATG 10mg/kg* * 
Flu 150mg/m2 
Cy 20mg/kg 
nil nil 34 Alive 
5534 F 
46 
Infection MUD 
PBSC 
Flu 150mg/m2, ** 
Cy 20mg/kg 
Alemtuzumab 
1mg/kg 
Grade 2 
Skin, gut 
nil 48 Alive 
5634 
 
72 
F 
Malignancy MUD 
PBSC 
Bu 2mg/kg** 
Flu150mg/m2 
ATG 7,5mg/kg 
nil nil 17 Alive 
5721, 34 
 
M 
165 
Malignancy MUD 
PBSC 
Bu 2mg/kg** 
Flu 150mg/m2, 
Grade 2 
Skin 
cGvHD 
Mild 
81 Alive 
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ATG 60mg/kg haemorrhagic 
cystitis 
5821 
 
M 
174 
Malignancy MMFD 
TCD 
PBSC 
Flu 160mg/m2,***  TT 
10mg/kg 
Melph 70mg/m2 
nil Mucositis, ITP, 
Sepsis, Adeno 
cryptosporidiosis 
24 Alive 
5934 
 
M 
102 
 
 
113 
Malignancy 
 
 
 
Malignancy 
relapse 
MSD 
BM 
 
 
MSD 
BM 
Flu (dose n/a)* 
Cy (dose n/a) 
 
 
Bu 12mg/kg*** 
Cy 120mg/kg 
 
Nil 
 
 
 
Gut 
Rejected 
 
 
 
sepsis 
11 
 
 
 
3 
Alive 
 
 
 
Dead 
6034 
 
F 
110 
Malignancy MSD 
BM 
Bu 2mg/kg** 
Flu 150mg/m2, 
ATG (dose n/a) 
 
nil Lymphoma 
relapse 
2 Dead 
6121, 34 
 
M 
192 
Malignancy MSD 
PBSC 
Bu 10mg/kg *** 
Cy 120mg/kg 
TT 25mg/kg 
nil nil Sepsis 
D+5 
Dead 
6234 
 
218 
M 
Malignancy 
 
MUD 
PBSC 
Flu150mg/m2* 
Melph 140mg/m2 
ATG (dose n/a) 
nil sepsis 6 Dead 
Reduced intensity conditioning regimen, ** Fanconi or modified Fanconi regimen, *** Myeloablative conditioning regimen.  
ATG, anti-thymocyte globulin; Bu, busulphan; Cy, cyclophosphamide; Flu, fludarabine; Melph, melphalan; TBI, total body 
irradiation; TT, thiotepa;  
 
ADV, adenovirus; AIHA, autoimmune haemolytic anaemia; BM, bone marrow; BMF, bone marrow failure; CB, cord blood; CMV, 
cytomegalovirus; EBV, Epstein-Barr virus; (a)(c)GvHD, (acute) (chronic) graft-versus-host disease; GI, gastrointestinal; HSCT, 
haematopoietic stem cell transplant; ITP, idiopathic thrombocytopenia; LPD, lymphoproliferative disease; MFD, matched family 
donor; MMFD, mismatched family donor; MOF, multi-organ failure; MUD, matched unrelated donor; n/a, not available; PBSC, 
peripheral blood stem cells; TCD, T cell depleted; TCRa/b, T cell receptor alpha/beta depletion; VOD, veno-occlusive disease 
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Table S3. Characteristics of patients with defects in NHEJ1. 
 
Patient Age in 
months 
at HSCT 
Sex 
Indication Donor/ 
Stem cell 
source 
conditioning GvHD Complications Follow up 
(months) 
Outcome 
New cases 
        
63 M 
5 
Infection MUD 
PBSC 
Flu 150mg/m2 *   
Cy 20 mg/kg 
Alemtuzumab 
1mg/kg 
Grade 4 
skin 
ADV 10 Alive 
64 M 
10 
Infection MSD 
BM 
Flu 150mg/m2 *   
Cy 20 mg/kg 
nil CMV 3 Alive 
65 F 
12 
SCID-like 
Infection 
MSD 
BM 
nil Grade 1 
aGvHD 
skin 
nil 76 Alive 
66 M 
17 
Infection MSD 
BM 
Cy 200mg/kg* 
ATG 60mg/kg 
nil nil 168 Alive 
67 M 
28 
Infection MSD 
BM 
Cy 200mg/kg * 
ATG 60mg/kg 
nil idiopathic 
pneumonitis  
166 Alive 
 
68 F 
48 
Infection MMUD 
CB 
Flu 150mg/m2 * *  
Cy 40mg/kg 
ATG 60mg/kg 
Grade 2 
skin 
CMV reactivation 24 Alive 
69 M 
100 
BMF MUD 6/6 
PBSC 
Flu 150mg/m2* * 
Cy 4mg/kg 
ATG 7.5mg/kg 
Grade 2, 
Skin 
Severe skin 
cGvHD with 
scleroderma and 
joint deformation 
Cachexia, 
oesophageal 
stenosis 
86 Alive 
70 F 
112 
Infection, 
cytopenia 
MSD 
BM 
Flu 150mg/m2* *  
Cy 40mg/kg  
Grade 1 
aGvHD 
lung cGvHD 
obstructive lung 
39 Alive 
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ATG 60mg/kg skin  disease 
71 M 
172 
Infection 
BMF 
MUD 10/10 
BM 
ATG 15mg/kg*** 
Treo 42mg/m2 
Flu 160mg/m2 
nil nil 7 Alive 
72 15 
M 
Autoimmune 
(AIHA) 
MUD 
CB 
Bu 6.4mg/kg*  
Flu 120mg/m2 
ATG 10mg/kg 
Grade 2, 
Skin 
Sepsis, EBV, 
myocarditis 
5 Dead 
73 41 
M 
Infection MUD 
BM 
Flu 150mg/m2,* * 
Cy 40mg/kg, 
Alemtuzumab 
1mg/kg 
Grade 3, 
Skin and 
Gut 
Pancreatitis, 
CMV, renal 
failure, HTN, 
seizures, 
myelofibrosis, 
hyperglycaemia 
12 Dead 
74 F 
108 
BMF MUD 4/6 
CB x2 
Flu 150mg/m2*  
Melph 140mg/m2 
Alemtuzumab 
1.5mg/kg 
Grade 3 
Gut 
cGvHD 
EBV, ADV 
13 Dead 
Published 
cases 
        
7525 
 
M 
10 
Infection MMUD 
PBSC 
Flu 120mg/m2 ** 
Cy 40mg/kg 
 ATG 15mg/kg 
Grade 2, 
Skin 
aGvHD  
cGvHD 
EBV-PTLD 
26 Alive 
7626 
 
F 
15 
Infection 
AIHA 
MSD 
BM 
nil nil nil 83 Alive 
7726 
 
F 
18 
Infection MSD 
BM 
nil Grade 4 
Gut 
nil 6 Alive 
7824 
 
F 
22 
Infection BM n/a n/a n/a n/a n/a 
7924 
 
M 
101 
Infection BM n/a n/a n/a n/a n/a 
Reduced intensity conditioning regimen, ** Fanconi or modified Fanconi regimen, *** Myeloablative conditioning regimen.  
ATG, anti-thymocyte globulin; Bu, busulphan; Cy, cyclophosphamide; Flu, fludarabine; Melph, melphalan; Treo, treosulphan; 
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ADV, adenovirus; AIHA, autoimmune haemolytic anaemia; BM, bone marrow; BMF, bone marrow failure; CB, cord blood; CMV, 
cytomegalovirus; EBV, Epstein-Barr virus; (a)(c)GvHD, (acute) (chronic) graft-versus-host disease; HTN, hypertension; MFD, 
matched family donor; MOF, multi-organ failure; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; n/a, not 
available; PBSC, peripheral blood stem cells; PTLD, post-transplant lymphoproliferative disease;  
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Table S4. Characteristics of patients with Ataxia Telangiectasia. 
 
Patient Age in 
months 
at HSCT 
Sex 
Indication Donor/ 
Stem cell 
source 
conditioning aGvHD Complications Follow up 
(months) 
Outcome 
New cases 
        
80 156 
M 
Malignancy MSD 
BM 
Bu 1.6mg/kg* *, 
Flu 180mg/m2 
Cy 40mg/kg, 
rituximab (dose n/a) 
nil haemorrhagic 
cystitis, VOD, 
Septicaemia, GI 
bleed 
27 Alive 
81 8 
M 
Infection MUD 
BM 
 
Treo 36mg/m2*** 
Flu 150mg/m2 
Alemtuzumab 1mg/kg 
Grade 1-
2 
skin 
EBV-PTLD 6 Dead 
82 22 
F 
BMF MFD 
BM 
Treo 46g/m2*** 
Flu 150mg/m2 
Grade 3, 
liver and 
skin 
PTLD, 
Hepatic failure 
20 Dead 
83 101 
F 
n/a MSD 
n/a 
Bu (dose n/a)*** 
Cy (dose n/a) 
Grade 2, 
skin and 
gut 
MOF 4 Dead 
84 138 
M 
Malignancy MFD 
PBSC 
Flu 150mg/m2,* * 
Cy 0.3mg/kg 
Grade 
(n/a) 
skin 
Extensive 
cGvHD skin 
Interstitial 
pneumonitis 
11 Dead 
85 144 
M 
Malignancy MSD 
BM 
Bu (dose n/a)*** 
Cy (dose n/a) 
Grade 2 
skin 
Pericardial 
effusion 
Hemorrhagic 
cystitis 
3 Dead 
Updated 
publication 
        
8627 54 
M 
ALL-T MSD 
BM 
Bu 2mg/kg,* * 
Flu 150mg/m2 
nil haemorrhagic 
cystitis, CMV 
48 Alive 
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ATG 80mg/kg, 
OKT3 (dose n/a)* 
reactivation 
8742 22 
M 
Infection MFD 
BM 
Treo 36g/m2*** 
Flu 150mg/m2 
ATG 60 mg/kg 
Grade 3 
Skin, 
liver 
fulminant hepatic 
failure,  
gammopathy,  
EBV reactivation, 
encephalopathy 
10 Dead 
Reduced intensity conditioning regimen, ** Fanconi or modified Fanconi regimen, *** Myeloablative conditioning regimen.  
ATG, anti-thymocyte globulin; Bu, busulphan; Cy, cyclophosphamide; Flu, fludarabine; OKT3, Muromonab-CD3; Treo, 
treosulphan 
 
BM, bone marrow; BMF, bone marrow failure; CMV, cytomegalovirus; EBV, Epstein-Barr virus; (a)(c)GvHD, (acute) (chronic) 
graft-versus-host disease; GI, gastrointestinal; MFD, matched family donor; MMFD, mismatched family donor; MOF, multi-organ 
failure; MUD, matched unrelated donor; n/a, not available; PBSC, peripheral blood stem cells; PTLD, post-transplant 
lymphoproliferative disease; VOD, veno-occlusive disease 
 
